A safety and pharmacodynamics study of temelimab, an antipathogenic human endogenous retrovirus type W envelope monoclonal antibody, in patients with type 1 diabetes.,Diabetes, Obesity and Metabolism

当前位置： X-MOL 学术 › Diabetes Obes. Metab. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

A safety and pharmacodynamics study of temelimab, an antipathogenic human endogenous retrovirus type W envelope monoclonal antibody, in patients with type 1 diabetes.
Diabetes, Obesity and Metabolism ( IF 5.8 ) Pub Date : 2020-02-19 , DOI: 10.1111/dom.14010
Francois Curtin _{1,

2} , Bernard Champion ₃ , Peter Davoren ₄ , Sally Duke ₅ , Elif I Ekinci ₆ , Chris Gilfillan ₇ , Claire Morbey ₈ , Thomas Nathow ₉ , Trisha O'Moore-Sullivan ₁₀ , David O'Neal ₁₁ , Adam Roberts ₁₂ , Stephen Stranks ₁₃ , Bronwyn Stuckey ₁₄ , Parind Vora ₁₅ , Sam Malpass ₁₆ , David Lloyd ₁₆ , Nicole Maëstracci-Beard ₁ , Bénédicte Buffet ₁ , Gabrielle Kornmann ₁ , Corinne Bernard ₁ , Hervé Porchet _{1,

17} , Richard Simpson ₇

Affiliation

GeNeuro SA, Geneva, Switzerland.
Division of Clinical Pharmacology and Toxicology, Rue Perret-Gentil, University of Geneva, Geneva, Switzerland.
Department of Clinical Medicine, Faculty of Medicine and Health Sciences, Macquarie University, Macquarie Park, New South Wales, Australia.
Gold Coast Hospital, Diabetes and Endocrinology, Southport, Queensland, Australia.
Department of Diabetes Endocrinology and Metabolism, Royal North Shore Hospital, St Leonards, New South Wales, Australia.
Department of Medicine, Austin Health and The University of Melbourne, Heidelberg Heights, Victoria, Australia.
Eastern Clinical Research Unit, Eastern Health and Monash University, Box Hill, Victoria, Australia.
AIM Centre, Merewether, New South Wales, Australia.
Ipswich Research Institute, Ipswich, Queensland, Australia.
Mater Hospital, South Brisbane, Queensland, Australia.
St. Vincent's Hospital, Department of Medicine, Fitzroy, Victoria, Australia.
Barwon Health, Department of Endocrinology, Geelong, Victoria, Australia.
Southern Adelaide Diabetes & Endocrine Services, Flinders Medical Centre, Bedford Park, South Australia, Australia.
Keogh Institute for Medical Research, Queen Elizabeth II Medical Centre, Nedlands,, Western Australia, Australia.
Division of Medicine, Lyell McEwin Hospital, Elizabeth Vale, South Australia, Australia.
Southern Star Research, Gordon, New South Wales, Australia.
Department of Pharmacology, University of Pretoria, Pretoria, South Africa.

To report the first study of temelimab, a monoclonal antibody neutralizing the pathogenic human endogenous retrovirus type W envelope, in patients with type 1 diabetes (T1D).

中文翻译：